Basic Information
Niuliva Solution For Infusion In Pre-Filled Syringe 600 I.U./2.4 ml
INJECTION, SOLUTION
Regulatory Information
SIN14068P
December 30, 2011
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 3, 2025
XJ06BB04
Company Information
Active Ingredients
Strength: 600 I.U./2.4 ml
Detailed Information
Contraindications
**Contraindications** Hypersensitivity to any of the components. (See special warnings about excipients, section “Special warnings and precautions for use” – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). Hypersensitivity to human immunoglobulins.
Indication Information
**Therapeutic indications** Niuliva® is indicated for: **Prevention of hepatitis B virus re-infection after liver transplantation for hepatitis B induced liver failure during the maintenance phase in non replicator patients.** **Immunoprophylaxis of hepatitis B** - In case of accidental exposure in non-immunised subjects (including persons whose vaccination is incomplete or status unknown). - In haemodialysed patients, until vaccination has become effective. - In the newborn of a hepatitis B virus carrier-mother. - In subjects who did not show an immune response (no measurable antihepatitis B antibodies) after vaccination and for whom a continuous prevention is necessary due to the continuous risk of being infected with hepatitis B.